FACS

Providence Saint John's Health Center and Mahmee Partner to Expand Breastfeeding Services and Enhance Maternal Health Care

Retrieved on: 
Thursday, January 11, 2024
Women, Parenting, Children, Hospitals, Baby, Maternity, Health Technology, Family, General Health, Consumer, Health, Patient, Hospital, Mother, RN, Lactation, Partnership, Insurance, Consultant, FACS, IBCLC, RNC, Nursing, FACOG, MSN, Safety, Vital signs, Parent, MPH

Providence Saint John's Health Center is today announcing a partnership with Mahmee, a wraparound maternal healthcare company, to expand lactation care, enrich the postpartum experience and provide seamless support for new parents when they leave the hospital.

Key Points: 
  • Providence Saint John's Health Center is today announcing a partnership with Mahmee, a wraparound maternal healthcare company, to expand lactation care, enrich the postpartum experience and provide seamless support for new parents when they leave the hospital.
  • In the month following delivery, Providence Saint John’s patients will have access to a complimentary Mahmee membership.
  • By working with Mahmee, we are expanding our impact on families by offering essential support services, including mental health care and remote patient monitoring."
  • While Providence Saint John's has long championed maternal health care support, the partnership with Mahmee marks a monumental stride in creating a safety net during the most vulnerable phase of childbirth: the postpartum period.

REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting

Retrieved on: 
Wednesday, January 10, 2024
Suprachoroidal drug delivery, ABBV, AAV, Hawaiian Eye, FACS, Diabetic retinopathy, AMD, Webcast, AbbVie, Phase, EST

ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI.

Key Points: 
  • ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI.
  • ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, diabetic retinopathy and other additional chronic retinal conditions.
  • Those who plan on participating are advised to join 15 minutes prior to the start time.
  • A replay of the webcast will also be available via the Company's investor website approximately two hours after the call's conclusion.

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Retrieved on: 
Thursday, January 4, 2024
FACS, Kidney transplantation, Heart, University, Tacrolimus, JDRF, Patient, EGFR, Glomerular filtration rate, Exercise, Pharmaceutical industry

IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones.

Key Points: 
  • IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones.
  • Amended the Phase 1b trial protocol to add a second cohort, now allowing enrollment of up to 24 trial participants who are undergoing kidney transplantation.
  • Dosed first participants in Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.
  • 2024: Dose the first islet cell transplant participant for the treatment of type 1 diabetes at the University of Chicago Transplantation Institute.

HSS Study Reveals Concerning Link Between Growth Hormone Therapy and Growth Plate Fractures in Children

Retrieved on: 
Thursday, January 4, 2024
Growth hormone, Patient, Quadriceps, Injury, Hospital, Food, FACS, Fracture, Turner syndrome, Risk, Adolescence, Hospital Records, Research, Prader–Willi syndrome, Hospital for Special Surgery, Tibia, HSS, Motion, Parent, Kidney disease, MPH, Journal, Child, Dentistry

NEW YORK, Jan. 4, 2024 /PRNewswire/ -- Human growth hormone has long been used to treat certain medical conditions in children. New research from surgeon-scientists at Hospital for Special Surgery (HSS) shows that there may be a previously unknown complication.

Key Points: 
  • In children, human growth hormone therapy has been used for decades to treat growth hormone deficiency due to underlying medical conditions such as Turner syndrome, very small weight at birth, Prader-Willi syndrome and chronic renal insufficiency.
  • Given the volume of patients we treat, we were able to investigate the relationship between tibia growth plate fractures and growth hormone therapy in pediatric patients."
  • Therefore, the odds of taking growth hormone therapy were 15 times higher among patients with proximal tibia physeal avulsion fractures than the comparison group.
  • "Further research is required to tease out whether limiting specific high-impact sports will mitigate the risk of tibia growth plate fractures in active children and adolescents."

Florida Cancer Specialists & Research Institute Welcomes Gynecologic Oncologist Bradley Monk, MD, FACOG, FACS To Lead Late-Phase Clinical Research Program

Retrieved on: 
Wednesday, January 3, 2024
FACS, Cervical cancer, Research, Hope, MD, Health, Cancer, Standard of care, FACOG, FCS, Patient, Safety, Oncology nursing

FORT MYERS, Fla., Jan. 3, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that board-certified gynecologic oncologist Bradley Monk, MD, FACOG, FACS has joined the statewide practice. As medical director of the FCS Late-Phase Clinical Research Program, Dr. Monk will lead innovative initiatives to expand and deploy late-phase trials that are transforming cancer care worldwide. He is also providing care to patients at the FCS Palm Beach location, 1309 N. Flagler Drive, West Palm Beach, FL 33401.

Key Points: 
  • FORT MYERS, Fla., Jan. 3, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that board-certified gynecologic oncologist Bradley Monk, MD, FACOG, FACS has joined the statewide practice.
  • As medical director of the FCS Late-Phase Clinical Research Program, Dr. Monk will lead innovative initiatives to expand and deploy late-phase trials that are transforming cancer care worldwide.
  • "We are delighted to welcome Dr. Monk to our practice," said Lucio N. Gordan, MD , FCS President & Managing Physician.
  • Dr. Monk has extensive leadership experience in practice-changing clinical research and the development of clinical research programs in community oncology settings.

The Inner Circle Acknowledges, Allan Lamb as a Pinnacle Platinum Healthcare Professional

Retrieved on: 
Friday, December 29, 2023
Liver, General surgery, Inner circle, American Osteopathic Association, University college, State, FACS, Stomach, Physician, Multimedia, Bile, Pancreas, Osteopathic medicine in Canada, Education, Advisory Committee, Earlham College, Appendix, Nursing, Professional, Esophagus, American College, Des Moines University, Committee, Patient, Thyroid, Henry Ford Health, Dentistry

TRENTON, Mich., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Allan Lamb is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the fields of General Surgery and Osteopathic Medicine.

Key Points: 
  • TRENTON, Mich., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Allan Lamb is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the fields of General Surgery and Osteopathic Medicine.
  • Dr. Lamb pursued higher education at Earlham College in 1989 where he earned a Bachelor of Arts degree.
  • He then attended Des Moines University College of Osteopathic Medicine in 1995 and received a Doctor of Osteopathic Medicine degree.
  • Dr. Lamb currently serves as an osteopathic physician and the President of Lakeshore Surgical Consultants PLC in Trenton, Michigan.

2023 Urology Care Foundation Research Scholar Awardees Announced

Retrieved on: 
Tuesday, December 19, 2023
University, Vanderbilt University Medical Center, Cancer, Ageing, Urology, Pelvic pain, Houston Methodist Hospital, Spinal cord, The, EZH2, Randomized controlled trial, System, DNMT, Memorial, Weill Cornell Medicine, Children, Patient, American Urological Association, Hospital, FACS, Ureteroscopy, Research, Cornell University, AUA, Prostate cancer, Doctor of Philosophy, Macrophage, Funding of science, Children's Hospital of Philadelphia, Nursing

BALTIMORE, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation, the official foundation of the AUA, are pleased to recognize 13 researchers as recipients of the 2023 Urology Care Foundation Research Scholar Awards.

Key Points: 
  • BALTIMORE, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation, the official foundation of the AUA, are pleased to recognize 13 researchers as recipients of the 2023 Urology Care Foundation Research Scholar Awards.
  • Research Scholar Awards support future research leaders and ensure they receive the necessary training and guidance for a successful research career.
  • "The Urology Care Foundation is dedicated to improving urologic health worldwide by supporting research, providing patient education materials, and promoting humanitarian initiatives,” said Harris M Nagler, MD, FACS, Urology Care Foundation President.
  • “We are proud of our 2023 awardees and recognize the substantial impact their work will have on advancing the field of urology.”
    To learn more about the Urology Care Foundation Research Scholar Awards visit: https://www.auanet.org/research-and-data/research-awards/aua-funding/res...

$20 Million Donation to Howard University Supports GRACE Grant Program

Retrieved on: 
Monday, December 11, 2023
FACS, EFC, Student, Pell, MBA, Graduation, Education, Federation, University, Denver Broncos, Face, GRACE, Howard University, Child, Nursing

WASHINGTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- A $20 million donation to Howard University from Carrie Walton Penner and Greg Penner will support the GRACE Grant Endowed Fund, an initiative to eliminate college costs and keep first-year students enrolled through graduation.

Key Points: 
  • WASHINGTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- A $20 million donation to Howard University from Carrie Walton Penner and Greg Penner will support the GRACE Grant Endowed Fund, an initiative to eliminate college costs and keep first-year students enrolled through graduation.
  • The GRACE (Graduation Retention Access to Continued Excellence) Grant program provides a 100% match to first-time undergraduate students who receive the maximum Pell Grant from the federal government, with additional funds available to students who have an expected family contribution (EFC) of $0.
  • The average four-year graduation rate for EFC $0 GRACE recipients is 42 percent higher than those in the same category who did not receive GRACE funds.
  • “The GRACE Grant program empowers students during a crucial moment in their academic lives through to college graduation.”
    Carrie and Greg added that they hope their support for the GRACE Grant program encourages others to do the same.

ALPHA AESTHETICS PARTNERS WELCOMES THE WILLIAMS CENTER AND DR. EDWIN WILLIAMS

Retrieved on: 
Tuesday, December 19, 2023
Partnership, Partner, FACS, AAFPRS, Plastic surgery, American Academy, Patient, Growth, The Williams Center

Founded in 1993 by Dr. Edwin Williams III, MD, FACS, The Williams Center has established itself as a leader in surgery and aesthetic medicine.

Key Points: 
  • Founded in 1993 by Dr. Edwin Williams III, MD, FACS, The Williams Center has established itself as a leader in surgery and aesthetic medicine.
  • This partnership with Alpha Aesthetics Partners underscores a shared commitment to clinical excellence and patient-centered care.
  • Dr. Edwin Williams shared his vision for the partnership, stating, "In partnering with Alpha Aesthetics Partners, we are poised to revolutionize the Aesthetic Medicine industry.
  • John Wheeler, CEO of Alpha Aesthetics Partners, added, "The collaboration with Dr. Ed Williams and the team at The Williams Center is a significant milestone for our organization.

Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma

Retrieved on: 
Friday, November 17, 2023
Sale, Efficacy, Food, Extremities, BLA, Ernest, Denver Health Medical Center, Risk, Surgeon, Clinical trial, Meta-analysis, Amputation, Constipation, Peripheral artery disease, HAV, Thrombocytopenia, Research, Death, FDA, FACS, Army, HUMA, Standard of care, Infection, File, University, Tachycardia, Vascular surgery, Doctor of Philosophy, Anemia, Evaluation, Common, Biologics license application, Saphenous, Injury, Trial of the century, Pharmaceutical industry, Medical imaging, Medical device, Fever, MD, Patient, Safety

DURHAM, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced the presentation of positive V005 Phase 2/3 clinical trial results of the investigational Human Acellular Vessel (HAV) in the treatment of vascular trauma, as well as results from the treatment of wartime injuries in Ukraine. The two presentations were made at the VEITHsymposium, a major vascular surgery conference in New York City. Results showed the HAV had higher rates of patency (blood flow), and lower rates of amputation and infection, compared to historic synthetic graft benchmarks. Humacyte plans to file a Biologics License Application (BLA) for the HAV for an indication in vascular trauma patients with the U.S. Food and Drug Administration (FDA) during the current quarter.

Key Points: 
  • The two presentations were made at the VEITHsymposium, a major vascular surgery conference in New York City.
  • Results showed the HAV had higher rates of patency (blood flow), and lower rates of amputation and infection, compared to historic synthetic graft benchmarks.
  • Fox, MD, FACS, Director of Vascular Surgery at the University of Maryland Capital Region, a clinical investigator in the V005 trial.
  • Common adverse events reported were anemia, vascular graft thrombosis, blood loss anemia, pyrexia, thrombocytopenia, constipation, nausea peripheral edema, and tachycardia.